Jiangsu Jibeier Pharmaceutical Co., Ltd.
SSE:688566.SS
28.15 (CNY) • At close June 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 896.534 | 860.933 | 654.731 | 509.694 | 565.974 | 542.519 | 484.961 | 452.325 | 444.423 |
| Cost of Revenue
| 95.255 | 95.154 | 76.169 | 62.12 | 62.868 | 63.888 | 64.167 | 67.203 | 68.617 |
| Gross Profit
| 801.279 | 765.779 | 578.562 | 447.574 | 503.105 | 478.631 | 420.794 | 385.122 | 375.806 |
| Gross Profit Ratio
| 0.894 | 0.889 | 0.884 | 0.878 | 0.889 | 0.882 | 0.868 | 0.851 | 0.846 |
| Reseach & Development Expenses
| 38.652 | 55.774 | 55.18 | 29.282 | 33.547 | 31.159 | 19.597 | 17.14 | 16.751 |
| General & Administrative Expenses
| 14.602 | 16.071 | 14.484 | 10.354 | 10.787 | 8.869 | 7.672 | 7.536 | 5.811 |
| Selling & Marketing Expenses
| 267.392 | 401.873 | 310.912 | 260.162 | 287.647 | 275.052 | 249.044 | 232.099 | 230.295 |
| SG&A
| 281.994 | 417.944 | 325.397 | 270.516 | 298.435 | 283.921 | 256.715 | 239.635 | 236.106 |
| Other Expenses
| 225.972 | -8.199 | 38.18 | 37.448 | 36.866 | 33.199 | -0.976 | -0.607 | 8.64 |
| Operating Expenses
| 546.618 | 516.664 | 418.757 | 337.246 | 368.848 | 348.28 | 309.299 | 292.039 | 291.588 |
| Operating Income
| 254.661 | 249.115 | 176.401 | 133.635 | 150.558 | 130.056 | 114.22 | 93.043 | 82.45 |
| Operating Income Ratio
| 0.284 | 0.289 | 0.269 | 0.262 | 0.266 | 0.24 | 0.236 | 0.206 | 0.186 |
| Total Other Income Expenses Net
| -1.3 | -1.636 | -1.866 | -1.072 | -2.03 | -0.272 | -0.976 | -0.607 | 8.64 |
| Income Before Tax
| 253.362 | 247.479 | 174.534 | 132.563 | 148.528 | 129.784 | 113.243 | 92.436 | 91.09 |
| Income Before Tax Ratio
| 0.283 | 0.287 | 0.267 | 0.26 | 0.262 | 0.239 | 0.234 | 0.204 | 0.205 |
| Income Tax Expense
| 34.386 | 28.711 | 20.271 | 18.216 | 18.671 | 17 | 16.326 | 14.825 | 13.237 |
| Net Income
| 219.328 | 219.088 | 154.668 | 114.901 | 129.718 | 112.915 | 96.612 | 77.524 | 76.94 |
| Net Income Ratio
| 0.245 | 0.254 | 0.236 | 0.225 | 0.229 | 0.208 | 0.199 | 0.171 | 0.173 |
| EPS
| 1.13 | 1.17 | 0.83 | 0.61 | 0.69 | 0.6 | 0.69 | 0.55 | 0.55 |
| EPS Diluted
| 1.13 | 1.17 | 0.83 | 0.61 | 0.69 | 0.6 | 0.69 | 0.55 | 0.55 |
| EBITDA
| 264.188 | 265.552 | 164.599 | 119.295 | 150.645 | 143 | 117.771 | 97.958 | 97.227 |
| EBITDA Ratio
| 0.295 | 0.308 | 0.251 | 0.234 | 0.266 | 0.264 | 0.243 | 0.217 | 0.219 |